Last reviewed · How we verify

Apatone®B — Competitive Intelligence Brief

Apatone®B (Apatone®B) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mPTP inhibitor. Area: Cardiovascular.

phase 2 mPTP inhibitor mPTP Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Apatone®B (Apatone®B) — IC-MedTech Corporation. Apatone B is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to prevent cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Apatone®B TARGET Apatone®B IC-MedTech Corporation phase 2 mPTP inhibitor mPTP

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mPTP inhibitor class)

  1. IC-MedTech Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apatone®B — Competitive Intelligence Brief. https://druglandscape.com/ci/apatoneb. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: